Smart Personalized Medical Platform for Cancer Diseases

癌症疾病智能个性化医疗平台

• 批准号: RGPIN-2020-06275
• 负责人: Miled, Amine
• 金额: $ 2.04万
• 依托单位: Université Laval
• 依托单位国家: 加拿大
• 项目类别: Discovery Grants Program - Individual
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-01-01 至 2023-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=754138
• 关键词: Smart; Personalized; Medical; Platform; Cancer

This research proposal consists in the design of a new generation of an optical molecular imaging system embedded in an organ-on-chip system. The goal of the imaging system is to measure the neurotransmitter concentration in real time to understand the impact of cancer cells on the brain's neural network and the efficiency of commercialized anti-cancer drugs in the treatment of brain cancer cells. The sensor we are proposing is original in that it uses a functionalized and selective ultra-stable nanoparticle embedded in a high density microfluid micro-cavity array to image neurotransmitter concentration distribution when cancer cells grow in brain tissue from one side and from the other side ton investigate the efficiency of cancer drug. From a technological standpoint, the sensor is based on the hybrid integration of microfluidic/electronic/microelectronic, optic, MEMS technologies and nanoparticles in one single system. We are especially interested in detecting the offset of the absorption shift of the functionalized ultra-stable gold nanoparticles with aptamers specific to neurotransmitters. Our goal is to be able to create a molecular imaging sensor using standard cameras. As such, it is the equivalent of the electronic lens of a microscope being able to detect molecular activity. The only way to currently observe molecules with optic lenses is by adding fluorophore markers. This involves the modification of the original solution and the loss of resolution, which is limited to 200 nm in most microscopes. The purpose of the system we are proposing to develop is to exceed this resolution limit by capturing the molecules with aptamers tied to the nanoparticles. This will modify the diameter of the molecule and thus absorption shift. Therefore, by detecting this shift, the neurotransmitter concentration can be determined. Our goal is to be able to detect the concentrations of at least two neurotransmitters (dopamine and ascorbic acid) in the order of the nanomoles at this stage of the research. We will also replicate the process for the serotonin, ?-aminobutyric acid, acetylcholine and glutamate neurotransmitters. We will therefore implement the first image sensor from selective gold nanoparticles for neurotransmitters. Such technology could be more widely used, beyond neuroscience, for example in the detection of drugs and water toxins.

本研究的目的在于设计一种新一代的嵌入在器官芯片系统中的光学分子成像系统。成像系统的目标是真实的测量神经递质浓度，以了解癌细胞对大脑神经网络的影响，以及商业化抗癌药物治疗脑癌细胞的效率。我们提出的传感器是原创性的，它使用嵌入在高密度微流体微腔阵列中的功能化和选择性超稳定纳米颗粒来从一侧成像脑组织中癌细胞生长时的神经递质浓度分布，并从另一侧研究癌症药物的效率。从技术的角度来看，传感器是基于微流体/电子/微电子，光学，MEMS技术和纳米粒子在一个单一的系统的混合集成。 我们特别感兴趣的是检测功能化的超稳定的金纳米粒子与特定于神经递质的适体的吸收位移的偏移。我们的目标是能够使用标准相机创建分子成像传感器。因此，它相当于能够检测分子活动的显微镜的电子透镜。目前用光学透镜观察分子的唯一方法是添加荧光团标记。这涉及到原始溶液的修改和分辨率的损失，在大多数显微镜中分辨率仅限于200 nm。我们提出开发的系统的目的是通过捕获与纳米颗粒结合的适体分子来超过这个分辨率限制。这将改变分子的直径，从而改变吸收位移。因此，通过检测这种变化，可以确定神经递质的浓度。我们的目标是在研究的这个阶段能够检测到至少两种神经递质（多巴胺和抗坏血酸）的浓度。我们还将复制血清素的过程，？-氨基丁酸、乙酰胆碱和谷氨酸神经递质。因此，我们将实现第一个图像传感器从选择性金纳米粒子的神经递质。这种技术可以在神经科学之外得到更广泛的应用，例如在检测药物和水毒素方面。